Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer

NCT04419181 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Change in the landscape of current treatment of early stage breast cancer. Larger clinical trials answering similar questions are expected to result in the next few years.

Conditions

HER2-positive Breast Cancer

Interventions

DRUG: Docetaxel
DRUG: Carboplatin
DRUG: Trastuzumab
DRUG: Pertuzumab
DRUG: Trastuzumab emtansine

Sponsor

University of Rochester